OncLive TV

Lindsay AM Rein, MD, discusses the TSS assessment from the SUMMIT trial investigating bezuclastinib in adult patients with non-advanced SM.

Rahul Banerjee, MD, FACP, discusses key considerations and unanswered questions regarding the selection between KRd and VRd in newly diagnosed myeloma.

Kevin Kalinsky, MD, MS, FASCO, discusses clinical data potentially supporting the use of TROP2-directed ADCs in frontline metastatic TNBC.

Lorenzo Falchi, MD, discusses the significance of the FDA approval of epcoritamab plus rituximab and lenalidomide for relapsed/ refractory follicular lymphoma.

David A. Russler-Germain, MD, PhD, discusses how data with MRD and ctDNA testing in solid tumors inform their potential application in hematologic malignancies.

Luciano Costa, MD, discusses teclistamab plus daratumumab vs investigator’s choice of DPd/DVd in patients with relapsed or refractory multiple myeloma.

Tsewang Tashi, MD, shares data from the PIONEER trial showing that avapritinib increases bone marrow density in patients with indolent systemic mastocytosis.

Jonathan Strosberg, MD, expands on subgroup analyses of outcomes with 177Lu-edotreotide in the COMPETE trial by tumor origin and prior lines of therapy.

Marcel Verheij, MD, PhD, discusses the use of chemotherapy vs CRT-containing strategies as a preferred preoperative regimen for resectable gastric cancer.

Stephen Lam Chan, MBBS, MD (CUHK), FRCP, discusses the lack of benefit with adjuvant pembrolizumab in HCC following a complete radiologic response.

Elena Elimova, MD, discusses efficacy data for zanidatamab in HER2-positive gastroesophageal adenocarcinoma from HERIZON-GEA-01.

Shuqiang Yuan, MD, PhD, outlines the most important data after 3 years of follow-up from the NEOSUMMIT-01 trial in locally advanced gastric/GEJ cancer.

Lorenzo Falchi, MD, expands on efficacy results from arms 6 and 7 of the phase 1b/2 EPCORE NHL-2 trial of epcoritamab in first-line follicular lymphoma.

Jacob Sands, MD, discusses the importance of multidisciplinary screening strategies for the identification of SCLC-associated LEMS.

Christof Vulsteke, MD, PhD, discusses the significance of the FDA approval of enfortumab vedotin plus pembrolizumab for cisplatin-ineligible MIBC.

Andrea Franson, MD, discusses the mechanism of action of tovorafenib and its emerging role within the evolving treatment paradigm for pLGG.

Joshua K. Sabari, MD, discusses the significance of the FDA approval of subcutaneous amivantamab for the treatment of patients with EGFR-mutant NSCLC.

Noa Biran, MD, highlighted the real-world use of the SKY92 gene expression profiling assay for multiple myeloma risk stratification.

Marlise Rachael Luskin, MD, MSCE, discusses the rationale, structure, and toxicity considerations of pediatric-inspired regimens in AYA ALL.

Yannis K. Valtis, MD, discusses real-world outcomes for obecabtagene autoleucel and brexucabtagene autoleucel in relapsed/refractory acute lymphoblastic leukemia.

Jacob Sands, MD, discusses challenges in the diagnosis and management of LEMS in patients with small cell lung cancer.

Joshua Richter, MD, elaborates on the best scenarios for certain CELMoD-based treatments for patients with multiple myeloma.

Sara M. Tolaney, MD, MPH, discusses updated safety data from ASCENT-04 evaluating sacituzumab govitecan plus pembrolizumab in PD-L1–positive TNBC.

Jason A. Mouabbi, MD, discusses the role of FES-PET/CT imaging in the diagnosis of lobular breast cancer.

Zev A. Wainberg, MD, discusses current available frontline chemotherapy regimens for patients with metastatic pancreatic cancer.

Tsewang Tashi, MD discusses updated long-term data for avapritinib in indolent systemic mastocytosis from part 3 of the PIONEER trial.

Zev A. Wainberg, MD, MSc, outlines factors informing his choice between standard frontline chemotherapy regimens in metastatic pancreatic cancer.

Dong Kim, MD, discusses the evolving decision-making process for selecting a frontline chemotherapy regimen in pancreatic cancer.

Adam Fox, MD, discusses the process and timing of ordering NGS testing for patients with NSCLC.

Andre Henri Goy, MD, discusses key developments in mantle cell lymphoma presented at the 2025 ASH Annual Meeting.